Columbia Laboratories' Molecular Profiles to Develop Topical & Oral Psoriasis Products for Telormedix
Pharmaceutical formulation development and manufacturing services
provider Molecular Profiles Ltd., a subsidiary of Columbia Laboratories,
Inc., (NASDAQ: CBRX) has been selected as the formulation development
partner for a major pan-European collaborative project.
The UK-based company has been chosen by clinical stage biopharmaceutical
company Telormedix SA (Telormedix) to develop both topical and solid
dosage formulations for the use in the treatment of psoriasis.
The project, operating under the acronym PAT (Psoriasis
Anti-inflammatory Treatment), will involve other consortium partners
Biopta, Midatech Biogune and the University Hospital Zurich. Telormedix
raised funding from the European Eurostars Programme to coordinate this
international research project for one of its promising drug candidates,